Extend Medicare's prescription drug out-of-pocket cap and insulin cap to people with private insurance.

Gilbert Ray Cisneros, Jr. · California · Democratic

policy impact 4.00 specificity 1.00 extraction confidence 98%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Contest this claim

Occurrences

Extend Medicare’s $2,000 annual prescription drug out-of-pocket cap—rising to $2,100 in 2026 under the Inflation Reduction Act (P.L. 117-169)—and its $35 monthly insulin cap to individuals with private insurance.

The plan commits to extending Medicare drug and insulin caps to privately insured people.

Rep. Cisneros Unveils Health Care Action Plan | Representative Gil Cisneros
primary · press_release · model gpt-5.4-mini

Evidence

legacy_unverified · Source version not recorded · locator unknown

GovInfo lists H.R. 6255 as introduced on November 21, 2025 and referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce. Its full title is to establish requirements for cost-sharing for certain insulin products.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The House bill that would extend an insulin cost-sharing cap to private insurance exists only as introduced and referred, with no enacted law or later official action found in the August 26-28, 2026 lookback window. Cisneros is not listed among the sponsor or initial cosponsors on this GovInfo record.

unresolved same_term

H.R. 6255 (IH) - Affordable Insulin Now Act
secondary · model gpt-5.5 · confidence 89%

Contest this evidence item

legacy_unverified · Source version not recorded · locator unknown

GovInfo lists H.R. 6166 as introduced on November 20, 2025 and referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce. Its full title includes establishing out-of-pocket limits on prescription drugs under private health insurance.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The House bill addressing private-insurance prescription drug out-of-pocket limits remains at introduction/referral status, so the broader private-insurance drug cap portion of the commitment has not been delivered as of August 28, 2026. No concrete delivery, reversal, or abandonment signal was found in the August 26-28 lookback window.

unresolved same_term

H.R. 6166 (IH) - Lowering Drug Costs for American Families Act
secondary · model gpt-5.5 · confidence 88%

Contest this evidence item

Assessments

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): unresolved. same_term

As of August 28, 2026, the promised federal outcome has not been enacted. The relevant House vehicles, H.R. 6166 for private-insurance prescription drug out-of-pocket limits and H.R. 6255 for insulin cost-sharing limits, were introduced and referred to committees but had not passed Congress or become law. The available evidence also does not show Cisneros as sponsor, initial cosponsor, or a material driver of those bills. Because the current congressional term is still ongoing and the policy has not definitively failed, this is unresolved rather than delivered or never.

provider codex_cli · model gpt-5.5 · confidence 88%